Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;17(2):181-7.
doi: 10.1080/15384047.2015.1108489. Epub 2015 Nov 17.

E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer

Angela Hong  1   2 , Xiaoying Zhang  3 , Deanna Jones  3 , Mei Zhang  1   2 , C Soon Lee  4 , J Guy Lyons  1 , Anne-Sophie Veillard  5 , Barbara Rose  3
Affiliations

E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer

Angela Hong et al. Cancer Biol Ther. 2016.

Abstract

The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) CONCLUSION: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.

Keywords: E6; head and neck cancer; human papillomavirus; oropharyngeal cancer; p16.

PubMed Disclaimer

Figures

Figure 1A.
Figure 1A.
Probability of remaining free of loco-regional recurrence by E6*I/*II ratio.
Figure 1B.
Figure 1B.
Event free survival by E6*I/*II ratio.
Figure 1C.
Figure 1C.
Overall survival by E6*I/*II ratio.
See this image and copyright information in PMC

References

    1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31:4550-9; PMID:24248688; http://dx.doi.org/ 10.1200/JCO.2013.50.3870 - DOI - PMC - PubMed
    1. Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O'Brien CJ, et al.. Squamous cell carcinoma of the oropharynx in australian males induced by human papillomavirus vaccine targets. Vaccine 2010; 28:3269-72; PMID:20226244; http://dx.doi.org/ 10.1016/j.vaccine.2010.02.098 - DOI - PubMed
    1. Hong AM, Martin A, Armstrong BK, Lee CS, Jones D, Chatfield MD, Zhang M, Harnett G, Clark J, Elliott M, et al: Human papillomavirus modifies the prognostic significance of t stage and possibly n stage in tonsillar cancer. Ann Oncol 2013; 1:215-9; PMID:22887467; http://dx.doi.org/ 10.1093/annonc/mds205 - DOI - PubMed
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al.. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35; PMID:20530316; http://dx.doi.org/ 10.1056/NEJMoa0912217 - DOI - PMC - PubMed
    1. Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, Clark JR, Milross CG, Kim J, O'Brien CJ, et al.. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010; 103:1510-7; PMID:20959828; http://dx.doi.org/ 10.1038/sj.bjc.6605944 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources